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Abstract
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The rare genetic recessive disease, hereditary vitamin D resistant rickets (HVDRR), is caused by
mutations in the vitamin D receptor (VDR) that result in resistance to the active hormone 1,25dihydroxyvitamin D3 (1,25-(OH)2D3 or calcitriol). In this study, we examined the VDR from a young
boy with clinical features of HVDRR including severe rickets, hypocalcemia, hypophosphatemia
and partial alopecia. The pattern of alopecia was very unusual with areas of total baldness, adjacent
to normal hair and regions of scant hair. The child failed to improve on oral calcium and vitamin D
therapy but his abnormal chemistries and his bone x-rays normalized with intravenous calcium
therapy. We found that the child was homozygous for a unique missense mutation in the VDR gene
that converted valine to methionine at amino acid 26 (V26M) in the VDR DNA-binding domain
(DBD). The mutant VDR was studied in the patient’s cultured skin fibroblasts and found to exhibit
normal [3H]1,25-(OH)2D3 binding and protein expression. However, the fibroblasts were
unresponsive to treatment with high concentrations of 1,25(OH)2D3 as demonstrated by their failure
to induce CYP24A1 gene expression, a marker of 1,25(OH)2D3 responsiveness. We recreated the
V26M mutation in the WT VDR and showed that in transfected COS-7 cells the mutation abolished
1,25(OH)2D3-mediated transactivation. The mutant VDR exhibited normal ligand-induced binding
to RXRα and to the coactivator DRIP205. However, the V26M mutation inhibited VDR binding to
a consensus vitamin D response element (VDRE).
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In summary, we have identified a novel V26M mutation in the VDR DBD as the molecular defect
in a patient with HVDRR and an unusual pattern of alopecia.
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The hormonally active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25-(OH)2D3 or
calcitriol) is critically important for the normal regulation of calcium and phosphate
metabolism and in bone and mineral homeostasis [1]. These calcitriol actions determine the
quality of bone mineralization and prevent rickets in children and osteomalacia in adults as
well as play a role in the prevention of osteoporosis. The biological actions of calcitriol are
mediated by the vitamin D receptor (VDR), a member of the steroid-thyroid-retinoid receptor
gene superfamily of nuclear transcription factors. In humans, heterogeneous mutations in the
VDR gene cause the rare recessive genetic disease known as hereditary vitamin D resistant
rickets (HVDRR) also known as vitamin D dependent rickets type II. A number of mutations
have been identified in the VDR and shown to be the molecular basis of HVDRR [2,3]. Patients
with HVDRR develop early onset rickets and have hypocalcemia, hypophosphatemia, elevated
serum calcitriol levels and secondary hyperparathyroidism. Some HVDRR patients also have
total body alopecia and may develop skin lesions or dermal cysts [2,3]. These latter findings
are similar to the disease atrichia with papular lesions (APL) caused by mutations in the hairless
gene (hr). The HR protein is a corepressor of the VDR, as well as thyroid hormone receptor
(TR) and retinoid-related orphan receptor (ROR) (6–8). In general children with VDR defects
that cause alopecia are unresponsive to oral calcium and vitamin D or calcitriol therapy and
require intravenous calcium infusions to bypass the defective VDR that prevents normal
calcium absorption in the intestine.
The VDR is composed of an N-terminal DNA binding domain (DBD) that mediates binding
and specificity of VDR-DNA interactions and a C-terminal ligand-binding domain (LBD) that
binds the ligand calcitriol. The LBD is composed of 12 α-helices and 3 β-sheets and contains
binding sites for coactivator and corepressor proteins. The VDR heterodimerizes with the
retinoid X receptor (RXR) the complex than binds to vitamin D response elements (VDREs)
in target gene promoters. Calcitriol binding to the VDR causes the repositioning of helix H12,
that contains an activation function 2 (AF-2) domain, allowing for the recruitment of
coactivators. Mutations have been identified in the VDR that disrupt ligand binding, DNA
binding, RXR heterodimerization and coactivator binding [2,3]. In this report, we describe a
novel mutation in the VDR DBD that disrupts DNA binding in a patient with HVDRR and
partial alopecia.

MATERIALS AND METHODS
Informed consent laboratory testing and cultured fibroblasts
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Informed consent was given by The Department of Social and Rehabilitation Services under
a Stanford University IRB approved protocol. Laboratory tests were performed by routine
methods using a Vitros chemistry analyzer (Ortho-Clinical Diagnostics, Rochester, NY) in the
Children Mercy Hospital clinical lab. 25(OH)D (combination of D2 and D3) was measured by
Liquid Chromatography Tandem Mass Spectrometry and 1,25(OH)2D was measured by
radioimmunoassay method at Quest Diagnostics (San Juan Capistrano, CA). PTH was
measured by chemiluminescent Immunlite immunoassay (Siemens, Los Angeles, CA). Dermal
fibroblasts were cultured from an interscapular skin biopsy of the patient as previously
described [4].
DNA isolation and sequencing
Genomic DNA was extracted from peripheral blood using the QIAamp DNA blood mini kit
following the manufacturers instructions (Qiagen, Valencia, CA). Exons 2-9 of the VDR gene
were amplified by PCR and directly sequenced at the Stanford protein and nucleic acid facility.
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[3H]1,25(OH)2D3 binding and immunoblotting
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Ligand binding assays with [3H]1,25(OH)2D3 were performed as previously described [5].
Hydroxyapatite was used to separate bound and free hormone. VDR antibody D-6 (Santa Cruz
Biotechnology, Santa Cruz, CA) was used to detect VDR by immunoblotting as previously
described [6]. The blots were developed using ECL Plus western blotting detection system (GE
Healthcare, Piscataway, NJ). Protein concentrations were determined by the Bradford method
[7].
CYP24A1 (24-Hydroxylase) gene induction
Fibroblasts were treated with and without 1,25(OH)2D3 (in ethanol) for 6 hr in medium
containing 1% calf serum. RNA was isolated from the patient’s fibroblasts using RNAeasy
spin columns (Qiagen). cDNA was prepared by reverse transcription using superscript III
cDNA synthesis kit (Invitrogen, Carlsbad, CA). CYP24A1 (upper primer 5′AGTATGGCAAGATTTTCCGC and lower primer 5′-CACTTCCCCTGGTTTCATTAG)
and TATA binding protein (TBP) (upper primer 5′-TGCTGAGAAGAGTGTGCTGGAG and
lower primer 5′-TCTGAATAGGCTGTGGGGTC) genes were then amplified from the cDNA
using SYBR-green qPCR kit (New England Biolabs, Ipswich, MA) and semi-quantified using
real time PCR as previously described [6]. Experiments were performed in triplicate with
duplicate determinations.
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Site-Directed Mutagenesis
Site-directed mutagenesis of the WT VDR cDNA in pSG5 (Stratagene, La Jolla, CA) was
performed using the QuickChange II XL site-directed mutagenesis kit (Stratagene). Clones
were verified by sequencing.
GST-pull down assays
WT and V26M mutant VDR proteins were synthesized using the TNT Quick-coupled in vitro
transcription/translation system (Promega, Madison, WI) and then incubated with GSTRXRα and GST-DRIP205 with vehicle or increasing concentrations of 1,25(OH)2D3. After
washing, the bound proteins were eluted with 2X sample buffer and subjected to
immunoblotting with the anti-VDR D-6 antibody [6].
Co-immunoprecipitation
HR and VDRs were expressed in COS-7 cells. Co-immunoprecipitation was performed as
previously described [8].
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Transactivation Assays
COS-7 cells were grown in DMEM containing 10% bovine growth serum (Hyclone, Logan,
UT) in 12-well tissue culture plates. Cells were transfected in triplicate with 62.5 ng/well WT
or mutant VDR expression plasmid and 125 ng/well rat 24-hydroxylase promoter VDREluciferase plasmid using 5 μl/well Polyfect transfection reagent (Qiagen). A renilla-luciferase
plasmid, pRLnull (5 ng/well) that served as an internal control for transfection efficiency was
included in each assay. Following a 16 hr transfection, the cells were incubated in DMEM
containing 1% bovine growth serum with vehicle (ethanol) or 1,25(OH)2D3 for 24 hrs. The
cells were then lysed in 250 μl of reporter lysis buffer reagent (Promega) and assayed for
luciferase activity using the Dual Luciferase Assay (Promega) and a Turner Design
luminometer (Turner Design, Sunnyvale, CA). VDR protein expression in the transfected cell
extracts was assayed by immunoblotting.
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RESULTS
Case report
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A male child was brought to the hospital at 13 months of age for evaluation of neglect, failure
to thrive, weight loss, constipation and abdominal distention. He was born to a 22 year-old
mother with severe mental retardation and cerebral palsy secondary to a perinatal event. His
birth weight was 3062 g and length 46 cm. At birth, he was noted to have a large umbilical
hernia and bilateral postaxial polydactyl of both hands and one foot which were surgically
ligated. The child is suspected of being the product of a half-brother and half-sister union. The
family history was negative for birth defects or other known genetic diseases except for
postaxial polydactyl in both mother and maternal grandmother. At 10 months of age, the child
had been seen in Neurology clinic for a seizure-like event. His total serum calcium at the time
was 6.9 mg/dl. His neurological examination had shown global developmental delay and
macrocephaly, with mild decrease in white matter and mild ventriculomegaly on MRI scan.
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At presentation to our service, the child was co-operative but was not active during his
examination. He was small for his age, weight 8.025 kg, length 65 cm and head circumference
51 cm. His head appeared disproportionately large for his size with large open anterior fontanel
(2.5 × 2.5 cm). The lateral and posterior fontanels were closed. The cranial sutures were normal.
There was mild frontal bossing. The distribution of hair was abnormal. He had patches of scalp
that were devoid of hair, while other regions had sparse hair, and still other areas had full hair
(Fig. 1A). Eyebrows were very sparse and some eyelashes were present. He had a rachitic
rosary over his chest, metaphyseal widening of his wrist and ankles, and bowing of his upper
and lower extremities. He had a wide nasal bridge and ear pits on the posterior lobe. The rest
of the examination was normal except for the pertinent findings of delayed dentition, a large
umbilical hernia and generalized developmental delay without a focal neurological deficit.
Evaluation at the time of his presentation included vision and hearing assessment that were
normal. The karyotype was normal 46, XY. An evaluation for an inborn error of metabolism
showed normal urinary amino acids, organic acids and oligosaccharides, and normal serum
lactate, ammonia, acylcarnitine, TSH, cortisol and normal AST and ALT. The enzymatic
studies for mucopolysaccharidoses on skin biopsy were normal.

NIH-PA Author Manuscript

At presentation, his serum chemistry panel showed normal serum electrolytes, albumin,
magnesium, and renal function. The evaluation of his calcium-bone status was extremely
abnormal with hypocalcemia and secondary hyperparathyroidism. His serum chemistry panel
revealed calcium (Ca) 7.4 mg/dL (iCa 0.96 mmol/L), phosphorus (P) 2.4 mg/dL, parathyroid
hormone (PTH) 1103 pg/ml and alkaline phosphatase (ALP) 893 U/L. His 25(OH)D was 15
ng/ml and 1,25(OH)2D3 200 pg/ml (see Table 1). Urine cAMP was elevated at 9.4 (normal
1.3–3.7 nmol/dL GFR) suggesting a normal response of renal tubules to elevated PTH. The
skeletal survey showed generalized osteopenia with advanced features of rickets. There was
cupping and fraying at the metaphyseal ends of long bones of upper and lower extremities and
widening of growth plates (Fig. 1B). There was no evidence of nephrocalcinosis on abdominal
ultrasound.
The initial biochemical presentation was suggestive of nutritional rickets but the elevated 1,25
(OH)2D3 levels and the severity of rickets both clinically and on x-rays had raised the
possibility of a diagnosis of non-nutritional rickets. He was initially treated as nutritional rickets
with ergorcalciferol, calcium and calcitriol. We found that even after adequate correction of
the 25(OH)D level, there was no evidence of healing of rickets on x-rays or improvement in
his serum Ca, P, ALP and PTH levels. An attempt was made to treat with supra-physiological
doses of calcitriol and calcium, but the child’s chemistry panel continued to show
unresponsiveness (see Table 1, Fig. 1B). During this 6 months period of oral therapy, his 25
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(OH)D levels ranged from 35–117 ng/ml, 1,25(OH)2D rose to 200–669 pg/ml, and iCa 0.92–
1.13 mmol/L. At this time, it became clear that the child was resistant to calcitriol and his DNA
was evaluated for a mutation in the VDR gene.
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Once a VDR mutation was confirmed (see below), and the child had failed therapy with oral
supra-physiological doses of calcitriol and calcium, it was decided to embark on intravenous
(IV) calcium therapy and placement of a central port. With the family’s agreement, IV calcium
therapy was initiated. IV calcium gluconate was administered at a dose of 550 mg of elemental
calcium given over a period of 10 hours, and was subsequently titrated based on his biochemical
response. The infusion was first increased to 600 mg over 10 hours, then decreased to 450 mg
over 15 hours, then to 450 mg over 20 hours and then to 400 mg over 20 hours. He responded
to IV calcium therapy with a slow correction of his serum Ca, P, ALP and PTH, and radiological
healing of his rickets (Table 1, Fig. 1B). The IV calcium therapy was complicated by multiple
central line infections with various organisms including Serratia, Citrobacter, Enterobacter,
Enterococcus and Staphylococcus species that failed to respond to conventional antibiotic
therapy necessitating central line removal. He underwent placement and removal of three
central ports and two Hickman lines during this 8 month period. To evaluate an immunologic
deficit as a cause of recurrent infection testing including blood count, T-and B-cell
enumeration, serological response to childhood immunization, serum immunoglobulins,
dihydrorhodamine oxidation, nitroblue tetrazolium reduction test, and mutation analysis for
chronic granulomatous disease were all normal other than a low superoxide production. The
comprehensive immunological work up failed to detect a defect that could explain his marked
predisposition to central line infections. Except for line infections, his infection history has
been otherwise unremarkable.
The family requested that we discontinue IV calcium therapy when his x-rays and mineral
metabolism showed improvement. At the time that the IVs were discontinued, the child showed
normal chemistries and improved x-rays, but no change in alopecia. On no therapy other than
400 units of ergocalciferol that he received with his multivitamin preparation, we observed a
subtle increasing trend in his ALP and PTH despite normal serum calcium levels (Table 1).
We then initiated high dose oral calcium therapy that seemed to stabilize the ALP and PTH at
elevated levels. Our plan is to reinstitute IV calcium therapy when the early changes of
hypocalcemia and rickets begin to appear on serum chemistries or x-rays. On his last follow
up examination at 36 months of age he had normal serum electrolytes, albumin and renal
function. His blood work showed serum Ca 8.8 mg/dL, P 4.0 mg/dL, PTH 218 pg/ml, ALP
379 U/L and 25(OH)D 27 ng/ml (Table 1, Fig 1B).
Molecular analyses of VDR gene
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Exons 2-9 of the patient’s VDR gene were amplified by PCR from DNA isolated from blood
and directly sequenced. A single G to A missense mutation was identified in exon 2 that
changed the codon for valine to methionine at amino acid 26 (V26M) (Fig. 2). The patient was
homozygous for the mutation with both alleles affected. No other mutations were found.
Sequence analyses of exon 2 also showed that the patient was homozygous f/f for the FokI
polymorphism that occurs in the translation initiation start site (data not shown) [9].
Analyses of the VDR in the patient’s fibroblasts
The patient’s VDR was analyzed using [3H]1,25(OH)2D3 binding assays and immunoblotting.
[3H]1,25(OH)2D3 binding in cell extracts from the patient’s fibroblast had a mean specific
binding of approximately 22 fmol/mg protein (data not shown) that is within the normal range
[10]. Immunoblotting demonstrated that the patient expressed the VDR V26M mutant at
similar levels to WT VDR expressed in normal control fibroblasts (Fig. 3A). To determine
whether the patient’s cells were resistant to 1,25(OH)2D3, we examined CYP24A1 induction
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using real-time RT-PCR. The patient’s fibroblasts and normal control fibroblasts were treated
with 1,25(OH)2D3 for 6 hr. As shown in Fig. 3B, the patient’s fibroblasts failed to induce
CYP24A1 in response to treatment with 1000 nM 1,25(OH)2D3 while the normal fibroblasts
exhibited an approximately 200-fold induction of CYP24A1 transcription in response to
treatment with 10 nM 1,25(OH)2D3. These results demonstrated that the patient’s fibroblasts
were resistant even to exceptionally high concentrations of 1,25(OH)2D3.
Transactivation
We recreated the V26M mutation in the VDR cDNA and examined the effects of the mutation
on VDR transactivation in COS-7 cells. As shown in Fig. 4A, WT VDR exhibited a dosedependent increase in luciferase activity in response to 1,25(OH)2D3 treatment. In contrast,
the V26M mutant VDR was unresponsive when treated with up to 1000 nM 1,25(OH)2D3.
Immunoblotting showed that both WT and mutant VDRs were expressed at similar levels (Fig
4B). These results demonstrated that the V26M mutation abolishes transactivation by the
mutant VDR.
RXR heterodimerization and DNA binding
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VDR transactivation involves heterodimerization with RXR and DNA binding. We first
determined whether the V26M mutation affected RXR heterodimerization. Using GST pulldown assays (Fig. 5A), we showed that the VDR V26M mutant was bound to GST-RXR in
the absence of 1,25(OH)2D3. Addition of 1,25(OH)2D3 increased the binding in a dosedependent manner similar to the WT VDR indicating normal RXR dimerization (Fig. 5A). The
V26M mutation was expected to interfere with VDR-DNA interactions. We examined VDRDNA binding in vitro using gel shift assays. As shown in Fig. 5B, a band shift was generated
by the WT VDR in the presence of 500 nM 1,25(OH)2D3. On the other hand, the V26M mutant
VDR failed to generate a band shift when treated with 500 nM 1,25(OH)2D3 demonstrating
that the mutation disrupts DNA binding. Together these results demonstrated that V26M
mutation inhibited DNA binding and not VDR-RXRα heterodimerization.
Coactivator-corepressor interactions
We also examined whether the V26M mutation affected VDR interactions with the coactivator
DRIP205. As expected, using GST pull-down assays both the WT VDR and the VDR V26M
mutant exhibited a dose-dependent increase in binding to GST-DRIP205 when treated with
1,25(OH)2D3 (Fig. 6A). These results demonstrated that V26M mutation does not affect VDR
interactions with coactivators. The data further demonstrate that DNA binding is not required
for either RXR dimerization or coactivator binding.
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The child in this study also had patchy alopecia thus, we were interested in determining the
effects of the V26M mutation on VDR interactions with HR. In co-IP assays, the V26M mutant
VDR was immunoprecipitated with FLAG-HR similar to WT VDR (Fig. 6B, lanes 4 and 6).
In the absence of transfected VDR, a small amount of endogenous VDR was
immunoprecipitated with the FLAG-HR from the COS-7 cell extract (Fig. 6B, lane 2). These
data indicate that the mutant VDR interacts with HR and suggests that the alopecia was not
caused by a disruption in protein-protein interaction.

DISCUSSION
The patient described in this report exhibited the classical clinical pattern of HVDRR [2,3].
Despite a VDR mutation that caused the VDR to be totally unresponsive to even high
concentrations of 1,25(OH)2D3, the patient’s serum chemistries and bone abnormalities were
reversed by high doses of IV infused calcium. Normalization of chemistries and x-rays took
approximately 26 weeks of IV therapy. As previously noted [2,3,11,12], phosphorous
Mol Genet Metab. Author manuscript; available in PMC 2011 January 1.
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supplementation was not necessary and phosphate was normalized along with suppression of
hyperparathyroidism with calcium supplementation alone. The findings again indicate that the
major defect in HVDRR is an inability to absorb calcium in the GI tract. Bypassing this step
using IV calcium to restore normocalcemia results in healing of the rickets and reversal of
secondary hyperparathyroidism and hypophosphatemia [2,3,11,12]. Although we know from
the work of many investigators that 1,25(OH)2D3 has many actions to regulate multiple
important target genes in bone [1], the radiologic healing of rickets can be accomplished merely
by normalizing the calcium concentration. Careful biopsy studies in VDR knockout mice do
demonstrate some subtle abnormalities in mice treated with a “rescue” diet that corrects the
serum chemistries and x-ray findings of rickets [13,14]. The resolution of the rachitic changes
on x-rays has been sustained in this child for at least 9 months on the last evaluation, although
minor biochemical changes have started to be apparent by 3 months following discontinuation
of IV calcium. Presumably the actions of vitamin D in bone in vivo are redundant and alternative
regulatory pathways can mostly compensate for the absence of 1,25(OH)2D3 action. Another
possibility is that non-genomic actions of the mutant VDR remain intact since the defect in
this case is limited to the DBD [15]. However, in other HVDRR cases with absent VDR due
to premature termination mutations, healing with IV calcium is also routinely seen [16]. The
data also show that the secondary hyperparathyroidism can be suppressed to normal by
restoring the serum calcium concentration to normal even in the absence of vitamin D action.
At present we are attempting to maintain normal serum calcium in the child without marked
elevation in serum PTH using treatment with high dose oral calcium (200 mg/kg/day) as
recently shown by Ma et al [12].
Several important clinical concepts that were learned while caring for this complicated child
include the following three points. (1) Short periods of IV calcium infusion (10–12 hours) only
suppress PTH transiently. The PTH is again elevated prior to the next infusion. In addition,
there is marked increase in urinary calcium at the end of the infusion, which could increase the
risk for nephrocalcinosis. We believe the optimal infusion time is 18–20 hours to allow at least
a few hours in the day for childhood activities. The calcium dose has to be titrated based on
serum Ca, P and PTH values, and urine Ca and P excretion. (2) We also treated the child with
a thiazide diuretic to decrease urinary calcium and to help prevent development of
nephrocalcinosis, which may be a complication of IV calcium therapy in children with
HVDRR. (3) During the early course of IV calcium therapy, the serum phosphorous is
depressed and the urinary phosphorous excretion is low despite markedly elevated levels of
PTH. Urinary and serum phosphorous start to increase without phosphate supplementation as
secondary hyperparathyroidism resolves the bone begins to heal. As previously noted [2,3,
11,12], one does not need to provide oral phosphorus supplementation despite very low levels
of serum phosphorous.
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The child was prone to opportunistic gram negative bacterial infections (Serratia, Citrobacter
and Enterobacter) with central ports that have no disruption in skin barrier, while the Hickman
lines which are associated with disruption in skin barrier from an exit site wound were infected
within one week of placement with Staphylococcus and Enteroccocus. Vitamin D has been
shown to be an important player in innate immunity [17,18]. Although the immunological
workup related to adaptive immunity was normal, we have not evaluated his innate immunity
that could be important in his marked predisposition to central line infections.
In this child, we identified a homozygous single base change in exon 2 that resulted in a V26M
mutation as the molecular basis for HVDRR. The V26M mutation is located in the first zinc
finger in the VDR DBD. Our functional analyses showed that V26M mutation abolished VDRmediated regulation of gene transcription due to the inability of the mutant VDR to bind to
DNA. The V26M mutation does not affect ligand binding, RXR heterodimerization or
interactions with coactivators or corepressors.
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A question that warrants discussion is why the parents who are heterozygous for this mutation
have no apparent symptoms of the disease. Most heterozygotes are asymptomatic [2,3].
However, in this case, the V26M mutant VDR is still able to form heterodimers with RXR and
interact with coactivators and therefore it can compete with the WT VDR for these critical
VDR-associated factors. This would raise the possibility of the mutant VDR allele potentially
being able to exhibit dominant negative activity squelching the WT VDR. One possible
explanation for this not happening is that the VDR is limiting in the cells and RXR or the
coactivators are not. Since RXR and coactivators are essential for the function of multiple
receptors, they are likely to be present in excess compared to the VDR. A second potential
explanation is that although the DBD mutant VDRs can form heterodimers with RXR and bind
coactivators in response to ligand, they cannot bind to DNA and therefore do not compete with
the WT VDR at VDREs in target gene promoters.
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A second question that warrants discussion is the basis of the child’s partial alopecia. The
pattern of alopecia is unusual and some hair is present but clearly, the overall pattern is very
abnormal. We have now seen scanty or sparse alopecia in several cases and in one recent case
normal hair adjacent to total alopecia [12]. The VDR and HR are thought to repress specific
gene(s) during the hair cycle and that mutations in VDR or HR cause alopecia by derepression
of these critical gene(s) whose protein products then disrupt the hair cycle [6,19–21]. We
showed that the VDR V26M mutant binds to HR and therefore the findings suggest that the
alopecia in this child was not due to the failure of the mutant VDR to interact with HR. Since
the major defect in this mutant VDR is defective DNA binding, the data also suggest that VDR
binding to DNA is a critical function of the VDR in its regulation of the hair cycle. Although
we [19–21] and others [22,23] have previously speculated that unliganded VDR, that is mutant
VDR unable to bind hormone, may still be able to regulate the hair cycle, the current data
suggest that VDR-HR activity to prevent alopecia is dependent on the VDR binding to DNA.
Whether this action requires ligand binding is not clear from the current findings. A possible
explanation for the regions of normal or sparse hair in this child is that the hair was present at
birth and has not undergone its first catagen. Most newborns loose their hair within the first
3–6 months thus it will be interesting to see if this child becomes alopecic as it gets older. To
date there has been no visible change in his alopecia for over two years.
In conclusion, we have identified a novel missense mutation in the VDR gene in a patient with
HVDRR and an unusual pattern of partial alopecia. The mutation substitutes methionine for a
highly conserved valine at amino acid 26 in the first zinc-finger module in the VDR DBD and
disrupts VDR-DNA interactions.
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Fig 1.
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Fig. 1A. Photo of child with partial alopecia. The child has an unusual pattern of scalp alopecia
with areas of baldness, areas of scanty hair and areas with fuller hair. He has reduced hair in
the eyebrows and lashes.
Fig. 1B. The figure shows sequential x-rays of wrist and knee. [A] The baseline x-rays at age
13 months show changes consistent with rickets. [B] The findings remain essentially
unchanged at age 19 months despite adequate supplementation of vitamin D and supraphysiological doses of elemental calcium and calcitriol. The x-rays show progressive healing
of rickets at 22 months [C], 24 months [D] and 27 months [E] while the child was receiving
intravenous calcium therapy. [F] The last follow up x-ray at 36 months, 9 months after
discontinuation of intravenous calcium therapy, shows no reversal in rachitic features.
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Fig. 2.
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A missense mutation was identified in exon 2 of the VDR gene. A unique missense (G to A)
was identified in exon 2 that changed the codon for valine to methionine at amino acid 26. A,
Exon 2 of the VDR gene was amplified by PCR and sequenced directly. The patient’s sequence
is shown in upper panel. The wild-type sequence is shown in the lower panel. B, Schematic
diagram of the VDR DNA-binding domain and zinc-finger structure. Arrow indicates the
location of the V26M mutation. Shaded circles represent conserved amino acid residues.
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Fig. 3.
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The patient’s fibroblasts express the V26M mutant VDR but are resistant to 1,25(OH)2D3. A,
VDR in cell extracts from the patient’s fibroblasts were analyzed by immunoblotting. B,
Induction of CYP24A1 gene expression by 1,25(OH)2D3 in the patient’s fibroblasts was
analyzed by real time RT-PCR. Cells were treated with vehicle or 100 nM 1,25(OH)2D3 for 6
hr. Values were normalized to TBP expression.
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Fig. 4.
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The recreated V26M mutant VDR is transcriptionally inactive. A, Functional activity analyzed
by transactivation assays. The WT and V26M mutant VDRs in pSG5 or the pSG5 vector were
transfected individually into COS-7 cells along with the CYP24A1 promoter luciferase
reporter. The cells were treated with graded concentrations of 1,25(OH)2D3 for 24 hr and
luciferase activity determined. The mutant VDR showed no stimulation of the CYP24A1
promoter as compared to the WT VDR that exhibited a dose-dependent stimulation of the
promoter activity. A small but significant amount of luciferase activity due to endogenous VDR
was observed in the pSG5 vector control. B, Immunoblot of VDRs expressed in COS-7 cells.
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Fig. 5.
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The V26M mutation disrupts DNA binding but not RXR heterodimerization. A, RXR
heterodimerization was analyzed by GST-pull down. In vitro synthesized VDRs were
incubated with GST-RXR in the presence of vehicle or graded concentrations of 1,25
(OH)2D3. The samples were subjected to GST-pull down assays and VDRs detected by
immunoblotting. B, DNA binding analyzed by gel shift. Cell extracts of COS-7 cells transfected
with WT VDR and VDR V26M cDNA expression vectors were incubated with a [32P]-labeled
VDRE consensus sequence with and without 500 nM 1,25(OH)2D3. The grey arrowhead
indicates non-specific bands. The black arrowhead indicates the VDR-VDRE complex.
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Fig. 6.
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The V26M mutation does not disrupt coactivator or corepressor interactions with VDR. A,
Coactivator interactions were analyzed by GST-pull down. In vitro synthesized VDRs were
incubated with GST-DRIP205 in the presence of vehicle or graded concentrations of 1,25
(OH)2D3. The samples were subjected to GST-pull down assays and VDRs detected by
immunoblotting. Both the WT and V26M mutant VDRs exhibited a ligand-dependent
interaction with GST-RXR and GST-DRIP205. B, Corepressor interactions were analyzed by
coIP. WT and mutant VDRs were co-expressed with FLAG-tagged human HR in COS-7 cells.
Cell extracts were prepared and proteins immunoprecipitated with anti-FLAG or non-specific
IgG antibodies. Co-immunoprecipitating VDR was detected by immunoblotting. HR
expression was detected using HR specific antibodies. No bands were observed with the nonspecific IgG control. In, input; α-VDR, immunoprecipitating antibody; IgG, non-specific
control immunoprecipitating antibody.
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800

4000
8000

18

600 mg over 10 hrs
450 mg over 15 hrs
400 mg over 20 hrs
400 mg over 20 hrs
400 mg over 20 hrs
400 mg over 20 hrs
400 mg over 20 hrs

21

22

23

24

25

26

27

None
None
None
1800
2400
3000

28

30

32

33

34

36

Following Intravenous Calcium Therapy

550 mg over 10 hrs

20

During Intravenous Calcium Therapy

19

800

2400

18

400

400

400

400

400

400

400

400

400

400

400

400

400

400

800

800

8000

800
1600

17

0

15

0

13

Ergocalciferol (units/day)

Calcium intake is reported as elemental calcium component of calcium carbonate.

*

Calcium Intake* (mg/day)

Prior to Intravenous Calcium Therapy

Reference Range

Age (months)

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6

6

1.5

1

0.4

0

Calcitriol (μg/day)

8.8

9.1

9.0

9.3

8.7

8.9

9.1

8.8

9.2

9.0

8.5

8.2

8.3

7.8

7.8

8.6

7.3

8.6

8.4

7.4

8.6–10.5

Serum Ca (mg/dL)

4.0

5.4

4.9

5.5

4.5

4.9

5.9

4.9

6.6

4.0

5.0

2.8

2.2

2.9

2.9

2.2

2.1

2

2.8

2.4

3.5–6.8

Serum P (mg/dl)

379

370

382

392

277

256

294

332

383

348

532

805

1039

851

485

725

529

920

1165

893

110–320

Serum ALP (U/L)

218

134

92

239

172

59

115

136

94

99

193

158

360

799

895

642

1147

1055

641

1103

7–75

Serum PTH (pg/ml)

The table shows the therapy administered to the child with calcium, erogocalciferol and calcitriol over a 2 year period. Representative changes in serum
levels for calcium (Ca), phosphorous (P), alkaline phosphatase (ALP) and parathyroid hormone (PTH) are also shown.
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